These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38290659)

  • 21. HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy.
    Liu T; Fang Y; Zhang H; Deng M; Gao B; Niu N; Yu J; Lee S; Kim J; Qin B; Xie F; Evans D; Wang L; Lou W; Lou Z
    Cancer Res; 2016 Feb; 76(3):572-81. PubMed ID: 26676747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor-derived interleukin 35 mediates the dissemination of gemcitabine resistance in pancreatic adenocarcinoma.
    Sun H; Ge Y; Liu J; Li Z; Li H; Zhao T; Wang X; Feng Y; Wang H; Gao S; Shi L; Yang S; Sun P; Chang A; Hao J; Huang C
    Oncogene; 2024 Mar; 43(11):776-788. PubMed ID: 38243080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PTBP3 promotes malignancy and hypoxia-induced chemoresistance in pancreatic cancer cells by ATG12 up-regulation.
    Ma J; Weng L; Jia Y; Liu B; Wu S; Xue L; Yin X; Mao A; Wang Z; Shang M
    J Cell Mol Med; 2020 Mar; 24(5):2917-2930. PubMed ID: 31989778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Wang Z; Chen Y; Lin Y; Wang X; Cui X; Zhang Z; Xian G; Qin C
    Int J Oncol; 2017 Oct; 51(4):1239-1248. PubMed ID: 28849150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.
    Tu Q; Liu X; Yao X; Li R; Liu G; Jiang H; Li K; Chen Q; Huang X; Chang Q; Xu G; Zhu H; Shi P; Zhao B
    J Exp Clin Cancer Res; 2022 Sep; 41(1):274. PubMed ID: 36109793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
    Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
    Ju HQ; Li H; Tian T; Lu YX; Bai L; Chen LZ; Sheng H; Mo HY; Zeng JB; Deng W; Chiao PJ; Xu RH
    J Pineal Res; 2016 Jan; 60(1):27-38. PubMed ID: 26445000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
    Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
    Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
    Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
    PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine.
    Miller AL; Fehling SC; Vance RB; Chen D; Brown EJ; Hossain MI; Heard EO; Andrabi SA; Wang H; Yang ES; Buchsbaum DJ; van Waardenburg RCAM; Bellis SL; Yoon KJ
    Cancer Lett; 2024 Jun; 592():216919. PubMed ID: 38704133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.
    Calabretta S; Bielli P; Passacantilli I; Pilozzi E; Fendrich V; Capurso G; Fave GD; Sette C
    Oncogene; 2016 Apr; 35(16):2031-9. PubMed ID: 26234680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1.
    Yu C; Su Y; Miao X; Chai C; Tang H; Li L; Yi J; Ye Z; Zhang H; Hu Z; Chen L; Li N; Xu H; Zhou W
    BMC Cancer; 2024 Jul; 24(1):800. PubMed ID: 38965506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma.
    Liu K; Geng Y; Wang L; Xu H; Zou M; Li Y; Zhao Z; Chen T; Xu F; Sun L; Wu S; Gu Y
    Mol Oncol; 2022 Aug; 16(16):3034-3051. PubMed ID: 35810469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts.
    Konaté MM; Krushkal J; Li MC; Chen L; Kotliarov Y; Palmisano A; Pauly R; Xie Q; Williams PM; McShane LM; Zhao Y
    J Transl Med; 2024 Aug; 22(1):733. PubMed ID: 39103840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
    She C; Wu C; Guo W; Xie Y; Li S; Liu W; Xu C; Li H; Cao P; Yang Y; Wang X; Chang A; Feng Y; Hao J
    J Exp Clin Cancer Res; 2023 Sep; 42(1):238. PubMed ID: 37697370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
    Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
    Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms.
    Yu X; Liu W; Wang Z; Wang H; Liu J; Huang C; Zhao T; Wang X; Gao S; Ma Y; Wu L; Li X; Yang S; Hao J
    Cancer Lett; 2021 Oct; 519():289-303. PubMed ID: 34302921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling.
    Yu S; Wang L; Che D; Zhang M; Li M; Naito M; Xin W; Zhou L
    J Exp Clin Cancer Res; 2022 Mar; 41(1):88. PubMed ID: 35260193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20.
    Yao J; Li Z; Wang X; Xu P; Zhao L; Qian J
    Acta Biochim Biophys Sin (Shanghai); 2016 Feb; 48(2):202-8. PubMed ID: 26758190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Ma L; Fan Z; Du G; Wang H
    Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.